Belgium
· Delayed Price · Currency is EUR Hyloris Pharmaceuticals Statistics
Total Valuation
Hyloris Pharmaceuticals has a market cap or net worth of EUR 168.00 million. The enterprise value is 139.06 million.
| Market Cap | 168.00M |
| Enterprise Value | 139.06M |
Important Dates
The next estimated earnings date is Tuesday, September 10, 2024.
| Earnings Date | Sep 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Hyloris Pharmaceuticals has 28.00 million shares outstanding.
| Shares Outstanding | 28.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 56.83% |
| Owned by Institutions (%) | 0.27% |
| Float | 12.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.87 |
| PB Ratio | 4.30 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.04 |
| EV / Sales | 33.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.61 |
Financial Position
The company has a current ratio of 5.22, with a Debt / Equity ratio of 4.48.
| Current Ratio | 5.22 |
| Quick Ratio | 5.14 |
| Debt / Equity | 4.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.13 |
| Interest Coverage | -304.73 |
Financial Efficiency
Return on equity (ROE) is -33.08% and return on invested capital (ROIC) is -20.72%.
| Return on Equity (ROE) | -33.08% |
| Return on Assets (ROA) | -18.27% |
| Return on Capital (ROIC) | -20.72% |
| Revenue Per Employee | 102,780 |
| Profits Per Employee | -375,122 |
| Employee Count | 41 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.26% in the last 52 weeks. The beta is 0.45, so Hyloris Pharmaceuticals's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -50.26% |
| 50-Day Moving Average | 9.00 |
| 200-Day Moving Average | 11.47 |
| Relative Strength Index (RSI) | 39.04 |
| Average Volume (20 Days) | 42,639 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hyloris Pharmaceuticals had revenue of EUR 4.21 million and -15.38 million in losses. Loss per share was -0.55.
| Revenue | 4.21M |
| Gross Profit | 4.12M |
| Operating Income | -15.85M |
| Pretax Income | -15.38M |
| Net Income | -15.38M |
| EBITDA | -15.74M |
| EBIT | -15.85M |
| Loss Per Share | -0.55 |
Balance Sheet
The company has 30.91 million in cash and 1.75 million in debt, giving a net cash position of 29.15 million or 1.04 per share.
| Cash & Cash Equivalents | 30.91M |
| Total Debt | 1.75M |
| Net Cash | 29.15M |
| Net Cash Per Share | 1.04 |
| Equity (Book Value) | 39.07M |
| Book Value Per Share | 1.40 |
| Working Capital | 28.55M |
Cash Flow
In the last 12 months, operating cash flow was -12.81 million and capital expenditures -298,000, giving a free cash flow of -13.11 million.
| Operating Cash Flow | -12.81M |
| Capital Expenditures | -298,000 |
| Free Cash Flow | -13.11M |
| FCF Per Share | -0.47 |
Margins
| Gross Margin | 97.79% |
| Operating Margin | -376.03% |
| Pretax Margin | -364.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -311.01% |
Dividends & Yields
Hyloris Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -9.17% |
| FCF Yield | -7.80% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |